drugset / Trial / NCT01112358
Lutropin Alfa in Women at Risk of Poor Response
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the effectiveness of adding lutropin alfa (recombinant human luteinizing hormone \[r-hLH\]) in the middle of the follicular phase compared to no addition, in infertile women at risk of poor response stimulated with follitropin alfa (recombinant Follicle-Stimulating Hormone \[r-FSH\]) under Gonadotropin Releasing Hormone (GnRH) antagonist in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), in the number and quality of oocytes, follicular development, fertilization oocyte, embryo quality, and pregnancy rate.
Timeline
- Start
- 2005-12-07
- Primary completion
- 2007-01-30
- Completion
- 2007-01-30
Publications
- Results M.J. Fernández Ramírez, A. Monzó, T. García-Gimeno, J.M. Rubio, V. Montañana, C. Duque, G. Herrero, A. Romeu. Role of LH administration during the follicullar phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF, REVISTA IBEROAMERICANA DE FERTILIDAD, Vol. 23- nº 5 - Septiembre-Octubre 2006
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | r-hLH | Protein / enzyme biologic | 150 iu | — |
| Background | Analogous GnRH antagonist | Unknown | — | — |
| Background | Progesterone | Other / unclassified | — | — |
| Background | Recombinant human follicle stimulating hormone (r-hFSH) | Protein / enzyme biologic | 225 iu | — |
| Background | Recombinant human follicle stimulating hormone (r-hFSH) | Protein / enzyme biologic | 450 iu | — |
| Background | r-hCG | Protein / enzyme biologic | 250 mg | Subcutaneous |